ClinicalTrials.gg
Not yet recruitingNCT07856342FOCUS IIUpdated Nov 17, 2026

Megagon Magnet Anastomosis Plus OTOLoc for Creating Colo-colonic and Colorectal Anastomoses

An interventional study of Megagon Self-Forming Magnet in Colo-rectal Anastomosis, Colo-rectal Cancer and Colo-rectal Surgery, sponsored by GI Windows, Inc.. Not yet recruiting. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GI Windows, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

The primary objective of this trial is to investigate the safety and effectiveness of the Megagon 28.5mm SFM system plus OTOLoc when used to create a colo-colonic and colorectal anastomosis in participants undergoing colon surgery. This will be evaluated via a composite safety/effectiveness endpoint of patient success defined as successful creation of the target anastomosis without placement procedure, device or target anastomosis related reoperation through 30 days.

Read the detailed description

This is a prospective, single-center, single-arm clinical study.

Patients who are scheduled for laparoscopic or hybrid colon surgery requiring an anastomosis will be evaluated for participation in the study.

Up to 30 participants undergoing colo-colonic and colorectal anastomoses with the Megagon 28.5mm SFM system plus OTOLoc.

Patients providing informed consent and meeting all eligibility criteria will be scheduled for surgery. All operations will be conducted by experienced general surgeons and gastroenterologists trained in the use of the Megagon SFM System plus OTOLoc, and procedures will be performed under general anesthesia. The anastomosis formation is achieved by creation of a colotomy in the (colon) utilizing a standard electrosurgical hook or equivalent, delivery of the OTOLoc into the colotomy, followed by delivery of the Megagon SFM through the OTOLoc into the colon with the FlexFire Universal 2, FlexFire delivery tools and the transrectal Nexus delivery system. Upon deployment, the SFM assembly self-forms into its closed octagonal shape and is ready for coupling with the second SFM. The same process is used for the second location in the rectum or colon. When the two SFMs are positioned to be in close proximity, coupling occurs, clamping the targeted intestinal tissue together, thereby starting the formation of a compression anastomosis.

After surgery, participants will be started on clear liquids and ambulation on the day of the procedure through postoperative Day 2. On postoperative Day 3, the diet will be advanced to full liquids excluding dairy products. On postoperative Day 5, participants may progress to a regular diet excluding all high-fiber foods (specifically vegetables, fruits, oatmeal, legumes, and other high-residue foods). Unrestricted regular diet will be permitted after postoperative Day 10. All dietary progression is subject to individual participant tolerance and investigator judgment. All participants will be required to stay in the hospital a minimum of one night per standard of care (SOC).

Clinical follow-up for all participants will occur at Discharge, Day 7, 30, and 60.

02

Conditions studied

  • Colo-rectal Anastomosis
  • Colo-rectal Cancer
  • Colo-rectal Surgery

Browse trials for

Keywords

  • Colo-rectal anastomosis
03

In context

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

This study's planned enrollment of 30 is below the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

GI Windows, Inc. is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 22 years or older at screening
  2. Candidate for surgery requiring Colo-colonic or colo-rectal (with anastomosis above the peritoneal reflection) with cardiac/medical clearance for surgery
  3. Able to understand and sign document
  4. (ASA) score \< IV at time of procedure
  5. All cancer patients must have completed chemotherapy ≥ 1 month prior to procedure
  6. Lives, and intends to remain, within a 300 kilometers radius of study center for the duration of the study
  7. Able to refrain from smoking during study follow-up period

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to silicone, nickel, titanium or Nitinol
  2. > 55 kg/m2
  3. Uncontrolled diabetes (defined as >10%)
  4. Congenital or acquired anomalies of the GI tract, including atresia or malrotation that would inhibit passing of SFM magnet
  5. Diagnosed with obstructed or perforated colon cancer
  6. Any documented conditions for which endoscopy and/or laparoscopy would be or history of previous technically difficult or failed endoscopy that may suggest difficulty for magnet passage
  7. Any previous major surgery on the stomach, duodenum, hepatobiliary tree, pancreas, Whipple or right colon
  8. Coagulation deficiency not normalized by medical treatment or count \<50,000/µL
  9. Known moderate to severe renal disease ( \< 44 milliliters per minute per 1.73m2) or ongoing dialysis
  10. Hyperkalemia / hypercoagulability or prior Venous Thromboembolism / Pulmonary Embolism
  11. (e.g., active treatment for , hematologic malignancy, on immunosuppressive therapy, moderate or severe primary immunodeficiency, advanced or untreated , active treatment with high-dose (i.e., 20 or more mg of prednisone or equivalent per day when administered for 2 or more weeks prior to surgery) or other immunosuppressive or immunomodulatory agents.

    • A minimum cessation window of four (4) weeks prior to surgery for all biologic agents
    • Restarted no earlier than four (4) weeks postoperatively
  12. Congestive heart failure with \<35% or arrhythmia (any rhythm disturbances except sinus tachycardia, sinus bradycardia or a sinus rhythm with premature atrial or ventricular complexes)
  13. Decompensated chronic obstructive lung disease
  14. Active or suspected infection at the surgical site or a CDC Class 3/contaminated or Class 4/dirty-infected surgical wound.
  15. Contraindication to general anesthesia
  16. Breast-feeding, pregnant, or planning on becoming pregnant during the follow-up period
  17. Currently participating or has participated in another clinical trial within the past 30 days and / or is receiving/has received an drug, device, or biologic agent within past 4 weeks
  18. Participant is not appropriate for inclusion in the clinical trial, per the medical opinion of the Principal Investigator
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Patients who are scheduled for laparoscopic or hybrid colon surgery requiring an anastomosis will be

    Anastomosis

    Device: Megagon Self-Forming Magnet

Interventions

  • DeviceMegagon Self-Forming Magnet

    Megagon Self-Forming Magnet

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    The study's primary endpoint (patient success) is defined as absence of hospitalization through 30 day endpoint. A successful anastomosis created with the Megagon SFM without placement procedure, device or target anastomosis-related reoperation through 30 days.

    Time frame: 30 Days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — Data is only feasibility data

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2026, 0 months later.

Of 404 interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Mar 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPrimary Endpoint: how it is measured was reworded
Nov 17, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 17, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPrimary Endpoint: how it is measured was reworded
    + 2 other changes: index terms and conditions
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856342
Lead sponsor
GI Windows, Inc.
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Peter Lukin COO
Contact
peter.lukin@giwindows.com
9787610183
Mohit Bhandari, MD
principal investigator · Mohak Hitech Specialty Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion